GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
➖
AI Sentiment
Neutral
5/10
- Home
- KYMR
as of 02-23-2026 3:33pm EST
$87.70
+$0.30
+0.34%
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 6.6B | IPO Year: | 2020 |
| Target Price: | $105.96 | AVG Volume (30 days): | 725.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.71 | EPS Growth: | -18.25 |
| 52 Week Low/High: | $19.45 - $103.00 | Next Earning Date: | 04-03-2026 |
| Revenue: | $47,072,000 | Revenue Growth: | -40.11% |
| Revenue Growth (this year): | 19.43% | Revenue Growth (next year): | -11.11% |
| P/E Ratio: | -32.25 | Index: | N/A |
| Free Cash Flow: | -207339000.0 | FCF Growth: | N/A |
AI-Powered KYMR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 76.73%
76.73%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Kymera Therapeutics Inc. (KYMR)
Esposito Pamela
Sell
Director
KYMR Feb 20, 2026
Avg Cost/Share
$87.58
Shares
2,500
Total Value
$218,270.01
Owned After
600
Esposito Pamela
Sell
Director
KYMR Jan 20, 2026
Avg Cost/Share
$67.73
Shares
5,500
Total Value
$373,521.12
Owned After
600
Mainolfi Nello
Sell
Chief Executive Officer
KYMR Dec 31, 2025
Avg Cost/Share
$78.23
Shares
30,000
Total Value
$2,341,939.35
Owned After
669,091
Esposito Pamela
Sell
Director
KYMR Dec 17, 2025
Avg Cost/Share
$82.85
Shares
27,563
Total Value
$2,264,480.27
Owned After
600
BAKER BROS. ADVISORS LP
Buy
Director, 10% Owner
KYMR Dec 11, 2025
Avg Cost/Share
$86.00
Shares
2,005,813
Total Value
$172,499,918.00
Owned After
701,326
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Esposito Pamela | KYMR | Director | Feb 20, 2026 | Sell | $87.58 | 2,500 | $218,270.01 | 600 | |
| Esposito Pamela | KYMR | Director | Jan 20, 2026 | Sell | $67.73 | 5,500 | $373,521.12 | 600 | |
| Mainolfi Nello | KYMR | Chief Executive Officer | Dec 31, 2025 | Sell | $78.23 | 30,000 | $2,341,939.35 | 669,091 | |
| Esposito Pamela | KYMR | Director | Dec 17, 2025 | Sell | $82.85 | 27,563 | $2,264,480.27 | 600 | |
| BAKER BROS. ADVISORS LP | KYMR | Director, 10% Owner | Dec 11, 2025 | Buy | $86.00 | 2,005,813 | $172,499,918.00 | 701,326 |
Latest Kymera Therapeutics Inc. News
KYMR Breaking Stock News: Dive into KYMR Ticker-Specific Updates for Smart Investing
Compare KYMR vs Leading Stocks
See how KYMR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KYMR Kymera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.